EcoDrugPlus

Si:dkey-211g8.6

Ensembl ID : ENSPNYG00000004770
Gene Symbol: SI:DKEY-211G8.6
1 Cross references
320 Possible Orthologues:

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSPNYG00000009842
Gene Symbol: SIGMAR1
3 Cross references
204 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSPNYG00000020571
Gene Symbol: SMO
3 Cross references
204 Possible Orthologues:

Sodium Channel Protein Type 4 Subunit Alpha B-Like

Ensembl ID : ENSPNYG00000017194
Gene Symbol: LOC102208917
3 Cross references
248 Possible Orthologues:

Sodium Channel Protein Type 5 Subunit Alpha-Like

Ensembl ID : ENSPNYG00000024245
Gene Symbol: LOC102206834
3 Cross references
256 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSPNYG00000015858
Gene Symbol: SCN4A
3 Cross references
191 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSPNYG00000022365
Gene Symbol: SCN8A
4 Cross references
216 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSPNYG00000021794
Gene Symbol: SCN8A
3 Cross references
215 Possible Orthologues:

Sodium- And Chloride-Dependent Gaba Transporter 1-Like

Ensembl ID : ENSPNYG00000004881
Gene Symbol: LOC102197154
3 Cross references
205 Possible Orthologues:

Sodium/glucose Cotransporter 1-Like

Ensembl ID : ENSPNYG00000011616
Gene Symbol: LOC102213479
3 Cross references
241 Possible Orthologues:

Sodium/glucose Cotransporter 1-Like

Ensembl ID : ENSPNYG00000011648
Gene Symbol: LOC102214147
3 Cross references
242 Possible Orthologues:

Sodium/glucose Cotransporter 1-Like

Ensembl ID : ENSPNYG00000011573
Gene Symbol: LOC102203546
3 Cross references
241 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).